• All
• March 28 (Thursday)
• March 29 (Friday)
• March 30 (Saturday)

Day-1 - March 28 (Thursday)

• Prospective studies for NK/T-cell lymphoma in Asia Seok Jin Kim
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• Chronic active EBV disease: Our challenge to elucidate the pathogenesis Ayako Arai
  St. Marianna University School of Medicine, Japan CV Abstract
• NK lymphoma genomics Weili Zhao
  Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China CV Abstract

Day-1 - March 28 (Thursday)

• Histiocytic neoplasm in pediatrics Kyung-Nam Koh
  University of Ulsan College of Medicine, Korea CV Abstract
• Histiocytic sarcoma Sungnam Lim
  Inje University College of Medicine, Korea CV Abstract
• Pathologic characteristics of histiocytic and dendritic cell neoplasms Sun Och Yoon
  Yonsei University College of Medicine, Korea CV Abstract

Day-1 - March 28 (Thursday)

• Elucidating the 3D chromatin landscape of pediatric B-cell acute lymphoblastic leukemia using Micro-C Kajsa Paulsson
  Lund University, Sweden CV Abstract
• Integrated RNA and protein profiling of B-cell acute lymphoblastic leukemia at single-cell level Sungyoung Choi
  Hanyang University College of Medicine, Korea CV Abstract
• Leveraging dysregulated signaling networks for therapeutic benefit in myeloproliferative neoplasm Stephen T. Oh
  Washington University School of Medicine, USA CV Abstract

Day-1 - March 28 (Thursday)

• Molecular mechanism of primary TKI
  resistance in CML Jerald Radich
  Fred Hutchinson Cancer Center, USA CV Abstract
• Targeting leukemic stem cells in CML Mhairi Copland
  University of Glasgow, UK CV Abstract
• The role of NGS to detect TKI resistance Saeam Shin
  Yonsei University College of Medicine, Korea CV Abstract

Day-1 - March 28 (Thursday)

• Somatic mutations and clonal dynamics in human blood cells Peter J. Campbell
  Wellcome Sanger Institute, UK CV Abstract

Day-1 - March 28 (Thursday)

• Lab-on-a-chip in hematology Chong H. Ahn
  University of Cincinnati, USA CV Abstract

Day-1 - March 28 (Thursday)

• Treatment of newly diagnosed multiple myeloma: Focus on daratumumab combination Elena Zamagni
  IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy CV Abstract

Day-1 - March 28 (Thursday)

• The ultimate value of C5 inhibitors in the evolving treatment landscape of PNH Sung-Hyun Kim
  Dong-A University College of Medicine, Korea CV Abstract

Day-1 - March 28 (Thursday)

• Treatment strategies for elderly AML with FLT3-mutation, entering the Era of FLT3 Inhibitors Naoko Hosono
  University of Fukui, Japan CV Abstract

Day-1 - March 28 (Thursday)

• Advances in the treatment paradigm with bispecific antibodies Wendy Osborne
  Newcastle University, UK CV Abstract

Day-1 - March 28 (Thursday)

• Dynamic assessment of risk in multiple myeloma Meral Beksac
  Ankara Liv Hospital affiliated with Istinye University, Türkiye CV Abstract
• PET/CT for risk stratification in multiple myeloma Joon Ho Moon
  Kyungpook National University School of Medicine, Korea CV
• Bone marrow inflammation in multiple myeloma Tom Cupedo
  Erasmus MC Cancer Center, The Netherlands CV Abstract
• Single-cell analysis in multiple myeloma Sung-Soo Park
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-1 - March 28 (Thursday)

• Approaches to treat people with hemophilia: What’s new and what’s not? Leonard A. Valentino
  Rush University, USA CV Abstract
• Prospects and challenges of gene therapy for hemophilia Alok Srivastava
  Christian Medical College, India CV Abstract
• Exploring personalized tailored hemophilia treatment: Tailoring treatment to individual needs Jeong A Park
  Inha University College of Medicine, Korea CV Abstract

Day-1 - March 28 (Thursday)

• CD7 CAR-T therapy for treating hematological malignancies Peihua Lu
  Lu Daopei Hospital, China CV Abstract
• Development of a novel anti-CD19 CAR-T cells in B cell lymphoma Dok Hyun Yoon
  University of Ulsan College of Medicine, Korea CV Abstract
• CAR-T cells for treatment of T cell malignancies Paul M. Maciocia
  Cancer Research UK , UK CV Abstract

Day-1 - March 28 (Thursday)

• Navigating cancer complexities via single-cell omics and AI Manoj Bhasin
  Emory University, USA CV Abstract
• Targeting the developmental heterogeneity of human acute myeloid leukemia Shanshan Pei
  Zhejiang University, China CV Abstract
• Mutational profile in Korean AML patients Jae-Sook Ahn
  Chonnam National University Medical School, Korea CV Abstract

Day-1 - March 28 (Thursday)

• Germinal center in the genesis of lymphomas Laura Pasqualucci
  Columbia University, USA CV
• Genomics of follicular lymphoma: Clinical implications? Robert Kridel
  University of Toronto, Canada CV Abstract
• Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: A multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression Jin Ho Paik
  Seoul National University College of Medicine, Korea CV Abstract

Day-1 - March 28 (Thursday)

• Molecular alterations and clinical implications in MDS Yasushi Miyazaki
  Nagasaki University, Japan CV Abstract
• Recent advances and future therapeutic strategies in MDS Guillermo Garcia-Manero
  The University of Texas MD Anderson Cancer Center, USA CV
• Current diagnostic challenges in MDS In-Suk Kim
  Pusan National University School of Medicine, Korea CV Abstract

Day-1 - March 28 (Thursday)

• RUNX1-FPDMM natural history study at NIH Pu Paul Liu
  National Institutes of Health, USA CV Abstract
• Clinical impact of DDX41 mutations in myeloid neoplasms Talha Badar
  Mayo Clinic, USA CV Abstract
• Discovery of new regulators in hematopoietic stem cells and malignancies Dongjun Lee
  Pusan National University School of Medicine, Korea CV Abstract

Day-1 - March 28 (Thursday)

• Overview of lymphoma classification Tae-Jung Kim
  The Catholic University of Korea College of Medicine, Korea CV Abstract
• What's new in AML classification Hee Sue Park
  Chungbuk National University College of Medicine, Korea CV Abstract
• Recent update of MDS classification Miyoung Kim
  University of Ulsan College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Pediatric and AYA ALL: Lessons learned from children’s oncology group clinical trials Sarah K. Tasian
  The Children’s Hospital of Philadelphia, USA CV Abstract
• Multicenter trials investigating childhood acute lymphoblastic leukemia in South Korea Hyery Kim
  University of Ulsan College of Medicine, Korea CV Abstract
• Dissecting the developmental origins of acute leukemia Charles G. Mullighan
  St. Jude Children’s Research Hospital, USA CV Abstract
• Unveiling precision medicine: RNA and DNA sequencing in targeted therapy for Korean pediatric leukemia Myungshin Kim
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Comprehensive overview of cell-based artificial platelet production Seung Yeob Lee
  Jeonbuk National University Medical School, Korea CV Abstract
• Anti-CD38 and anti-CD47 delay timely transfusion Hyungsuk Kim
  Seoul National University College of Medicine, Korea CV Abstract
• Reappraisal of transfusion-transmitted infections Dae-Hyun Ko
  University of Ulsan College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Clonal hematopoiesis and aging Siddhartha Jaiswal
  Stanford University School of Medicine, USA CV Abstract
• Clonal hematopoiesis: Implications for cell therapy Adam S. Sperling
  Dana-Farber Cancer Institute, USA CV Abstract
• Clonal hematopoiesis and metabolic diseases Sung Hee Choi
  Seoul National University College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• The impact of immune profiling of T-cell and plasma cells on non-cellular immune therapy in myeloma Nizar Jacques Bahlis
  University of Calgary, Canada CV Abstract
• Single-cell techniques to characterize immune microenvironment in MM Niels Weinhold
  Heidelberg University, Germany CV Abstract
• The power of ONE: Immunology in the age of single cell genomics Ido Amit
  Weizmann Institute of Science, Israel CV Abstract

Day-2 - March 29 (Friday)

• How to win: Competitive strategies in the hematopoietic stem cell niche Margaret Goodell
  Baylor College of Medicine, USA CV Abstract

Day-2 - March 29 (Friday)

• Continued Hope with ONUREG - A New Maintenance therapy to treat AML Esther Oliva
  Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Italy CV Abstract

Day-2 - March 29 (Friday)

• Mogamulizumab: A new era in MF/SS management - Clinical evidence and practical consideration Francine Foss
  Yale University School of Medicine, USA CV

Day-2 - March 29 (Friday)

• TKI treatment pattern and new therapy of CML Qian Jiang
  Peking University People's Hospital, China CV Abstract

Day-2 - March 29 (Friday)

• The optimal treatment strategy for transplant-ineligible relapsed/refractory DLBCL Kwai Han Yoo
  Gachon University College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• The journey of bone marrow transplantation at BachMai General Hospital Han Viet Trung
  Bach Mai Hospital, Vietnam CV Abstract
• Current situation of management of Non-Hodgkin lymphoma in the Republic of Armenia Yervand Hakobyan
  Armenian Hematology Association, Armenia CV Abstract
• The evolution of hemophilia treatment in Thailand Darintr Sosothikul
  Chulalongkorn University, Thailand CV Abstract

Day-2 - March 29 (Friday)

• Palliative care for patients with leukemia Min Sun Kim
  Seoul National University College of Medicine, Korea CV Abstract
• Long-term survivorship in hematologic malignancies Shahrukh K. Hashmi
  Mayo Clinic, UAE CV Abstract
• The importance of monitoring symptoms and quality of life in routine hematology practice Fabio Efficace
  Italian Group for Adult Hematologic Diseases, Italy CV Abstract

Day-2 - March 29 (Friday)

• Novel approaches for diagnosis & treatment of acute lymphoblastic and myeloid leukemia Michel Zwaan
  Princess Máxima Center for Pediatric Oncology, The Netherlands CV Abstract
• The role of blinatumomab in the treatment of MRD negative B-ALL in adults Mark R. Litzow
  Mayo Clinic, USA CV Abstract
• Revised WHO classification of ALL: New era of genetic diagnosis Ari Ahn
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• AL cardiac amyloidosis Darae Kim
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• Nephrologist’s perspective on monoclonal gammopathy of renal significance Soon Hyo Kwon
  Soonchunhyang University College of Medicine, Korea CV Abstract
• Monoclonal gammopathies of neurological significance Ju-Hong Min
  Sungkyunkwan University School of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Clonal evolution of MDS/AML in patients with cancer predisposition syndromes Kenichi Yoshida
  National Cancer Center Research Institute, Japan CV Abstract
• Congenital and acquired thrombophilia in children Leonardo R. Brandão
  University of Toronto, Canada CV Abstract
• Management of rare pediatric lymphomas Jae Wook Lee
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Epidemiology, risk stratification and treatment outcome in acute myeloid treatment: Taiwan experience Hsin-An Hou
  National Taiwan University, Taiwan CV Abstract
• Advancement in leukaemia diagnostics: The role of next-generation sequencing (NGS) in acute myeloid leukaemia in Malaysia Angeli Ambayya
  Ministry of Health, Malaysia CV Abstract
• Determining fitness for treatments in older adults with AML Byung Sik Cho
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-2 - March 29 (Friday)

• Back to the basic: Coagulation pathway Seonyang Park
  Inje University College of Medicine, Korea CV Abstract
• Pharmacology: Anticoagulants and reversal agents Seo-Yeon Ahn
  Chonnam National University Medical School, Korea CV
• Proper application of anticoagulation therapy on cancer associated thrombosis Ho-Young Yhim
  Jeonbuk National University Medical School, Korea CV

Day-3 - March 30 (Saturday)

• Functional iron deficiency in cancer patients Ik-Chan Song
  Chungnam National University College of Medicine, Korea CV Abstract
• Assessment of neutropenia in hospitalized patients Young Hoon Park
  Ewha Womans University College of Medicine, Korea CV Abstract
• Perioperative consultation for the appropriate transfusion Ka-Won Kang
  Korea University College of Medicine, Korea CV Abstract

Day-3 - March 30 (Saturday)

• Myeloproliferative neoplasms and inflammation Steffen Koschmieder
  RWTH Aachen University, Germany CV Abstract
• Signaling contributing to the development of myelofibrosis: Beyond JAK/STAT Douglas Tremblay
  Mount Sinai School of Medicine, USA CV Abstract
• Clonal evolution in myelofibrosis Sung-Eun Lee
  The Catholic University of Korea College of Medicine, Korea CV Abstract

Day-3 - March 30 (Saturday)

• Treatment options for relapsed/refractory hodgkin lymphoma after brentuximab vedotin and PD-1 blockade Alex F. Herrera
  City of Hope, USA CV Abstract
• Aggressive B-cell lymphomas: Immuno-chemotherapies other than CAR-T cell therapies Jason Westin
  MD Anderson Cancer Center, USA CV
• Extranodal NK/T cell lymphoma: The immunogenic tumor Won Seog Kim
  Sungkyunkwan University School of Medicine, Korea CV

Day-3 - March 30 (Saturday)

• Genomic technologies for detecting structural variations in hematologic malignancies Miae Jang
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• The role of NGS in hematologic malignancies Young-Uk Cho
  University of Ulsan College of Medicine, Korea CV Abstract
• Germline predisposition to hematologic malignancies Sang Mee Hwang
  Seoul National University College of Medicine, Korea CV Abstract